Search

Displaying results 1201 - 1210 of 3388 in total
  1. Drug

    Dabigatran etexilate

    go.drugbank.com/drugs/DB06695
    ApprovedInvestigational

    Dabigatran etexilate is an oral prodrug that is hydrolyzed to the competitive and reversible direct thrombin inhibitor dabigatran. Dabigatran etexilate may be used to decrease the risk of venous thromboembolic events in patients in whom ...

    Categories: P-glycoprotein substrates
  2. Drug

    PF-04995274

    go.drugbank.com/drugs/DB12675
    Investigational

    Pf 04995274 is under investigation in clinical trial NCT01193062 (Study In Healthy Subjects To Evaluate The Changes In The Protein sAPP-Alpha In Cerebrospinal Fluid Following A Single Oral Dose Of PF-04995274

  3. Drug

    Rabeprazole

    go.drugbank.com/drugs/DB01129
    ApprovedInvestigational

    Rabeprazole is an antiulcer drug in the class of proton pump inhibitors. It is a prodrug - in the acid environment of the parietal cells it turns into active sulphenamide form. Rabeprazole inhibits the H+, K+ATPase of the coating gastric...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Inducers
  4. Drug

    Protego-PD

    go.drugbank.com/drugs/DB18279
    Experimental

    Protego-PD is a post-delivery placental extract.

    Synonyms: Protego-PD
  5. Drug

    Bosutinib

    go.drugbank.com/drugs/DB06616
    ApprovedInvestigational

    -alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph … [A6901,A17961] Bosutinib was first approved by the FDA in 2012 for the treatment of adult chronic, accelerated, or blast-phase Ph+ CML with resistance or intolerance to prior therapy.

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  6. Drug

    PF-232798

    go.drugbank.com/drugs/DB14813
    Investigational

    PF-232798 is under investigation in clinical trial NCT01140425 (Study To Evaluate The Effect Of A Multiple Oral Dose Of PF-00232798 On QT Intervals In Healthy Subjects).

    Categories: CCR5 Receptor AntagonistsSynonyms: PF-00232798
  7. Drug

    PF-06751979

    go.drugbank.com/drugs/DB15105
    Investigational

    PF-06751979 is under investigation in clinical trial NCT03126721 (The Study is to Evaluate the Effect of Multiple Doses PF-06751979 on the Pharmacokinetics of Midazolam in Healthy Adults).

  8. Drug

    Maftivimab

    go.drugbank.com/drugs/DB15899
    ApprovedInvestigational

    [A221825, A221830] A recent large-scale study elucidated that both neutralizing and Fc-mediated functions of antibodies were important for therapeutic benefit in animal models of EBOV infection.

  9. Drug

    Milnacipran

    go.drugbank.com/drugs/DB04896
    ApprovedInvestigational

    Moreover, recent research has shown that the levorotatory enantiomer of milnacipran, levomilnacipran, may have the capacity to inhibit the activity of beta-site amyloid precursor protein cleaving enzyme

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Inhibitors
  10. Drug

    Ulipristal

    go.drugbank.com/drugs/DB08867
    ApprovedInvestigational

    A recent systematic review proclaimed that the majority of available evidence demonstrates an inhibitory effect on ovulation rather than a post-fertilization effect on the endometrium, which has been heavily … It also binds to glucocorticoid receptor, however compared to mifepristone (a progesterone receptor antagonist), ulipristal is more tolerable and has lower glucocorticoid activity and better binding affinity

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates